A unique inhibitor conformation selectively targets the DNA polymerase PolC of Gram-positive priority pathogens
Infections with antimicrobial resistant pathogens are a major threat to human health. Inhibitors of the replicative polymerase PolC are a promising novel class of antimicrobials against Gram-positive pathogens, but the structural basis for their activity remains unknown. The first-in-class PolC-targeting antimicrobial, ibezapolstat, is a guanine analogue in late-stage clinical development for the treatment of Clostridioides difficile infections, and related inhibitors are being developed for systemic treatment of infections with methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Here, we present the cryo-electron microscopy structures of Enterococcus faecium PolC bound to DNA and in complex with ibezapolstat or the previously-undescribed inhibitor ACX-801. Both inhibitors form base-pairing interactions with the DNA in the active site, thereby competing with incoming dGTP nucleotides. We identify a crucial susceptibility determinant in PolC that is conserved in other organisms, such as C. difficile. This is explained by an unusual non-planar conformation of the inhibitors that induce a binding pocket in PolC. By combining structural, biochemical, bioinformatic and genetic analyses, this work lays the foundation for the rational development of an innovative class of antimicrobials against Gram-positive priority pathogens.
Authors
- Michael R. Barbachyn (ORCID: https://orcid.org/0000-0003-1198-1345)
- Michael H. Silverman (ORCID: https://orcid.org/0000-0002-6651-646X)
- Mia Urem (ORCID: https://orcid.org/0000-0002-8259-3991)
- Annemieke H. Friggen (ORCID: https://orcid.org/0000-0001-5780-2053)
- Meindert H. Lamers (ORCID: https://orcid.org/0000-0002-4205-1338)
- Wiep Klaas Smits (ORCID: https://orcid.org/0000-0002-7409-2847)
- Christopher J. Swain (ORCID: https://orcid.org/0000-0002-9636-4567)
- Lawrence I. Mortin (ORCID: https://orcid.org/0000-0002-7653-4135)
- Xiang Yu (ORCID: https://orcid.org/0000-0003-1903-0392)
- Robert J. DeLuccia (ORCID: https://orcid.org/0000-0003-0802-2151)
- Nina Musch (ORCID: https://orcid.org/0009-0006-8713-0888)
Institutions
- Charles River Laboratories (Netherlands) (NL)
- Calvin University (US)
- Leiden University Medical Center (NL)
- Eloxx Pharmaceuticals (United States) (US)
- Netherlands Metabolomics Centre (NL)
- Centre for Human Drug Research (NL)
Publication Details
- Journal
- Nature Communications
- Published
- 2025-11-06
- DOI
- https://doi.org/10.1038/s41467-025-65324-8
- Citations
- 1
- Primary Topic
- Bacterial Genetics and Biotechnology
- Type
- article
- Field-Weighted Citation Impact
- 1.82
Funders
- Netherlands Centre for Electron Nanoscopy
- Health~Holland
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek